Brian Daniel Webster, who serves as president and chief executive officer of Kestra Medical Technologies, LTD. (NASDAQ:KMTS), completed the sale of 15,000 common shares on April 15, 2026, generating proceeds of approximately $300,670.
The shares changed hands at a weighted average price of $20.0447 each, with individual trade prices spanning from $20.0000 to $20.2200. After this disposition, Webster retains direct ownership of 349,786 Kestra Medical shares.
The sale was carried out pursuant to a pre-established Rule 10b5-1 trading plan that Webster adopted on September 29, 2025. The use of such a plan indicates the transaction followed a prearranged schedule or formula for selling shares, rather than being a discretionary, day-of decision.
Separately, Kestra Medical’s third-quarter 2026 financial results reflected a mixed picture. The company reported earnings per share of -$0.61, which missed the consensus expectation of -$0.42. At the same time, revenue exceeded forecasts by nearly 7%, according to Piper Sandler.
Piper Sandler also flagged strong gross margin performance and noted that the adjusted EBITDA loss was narrower than anticipated. Those operating metrics, combined with the revenue upside, underpinned continued analyst confidence following investor discussions with company management.
Following investor meetings, BTIG reiterated a Buy rating on Kestra Medical and kept a $32.00 price target. Piper Sandler likewise reaffirmed an Overweight rating and maintained a $30.00 price target. Both firms’ continued positive stances point to constructive sentiment among these analysts despite the EPS miss.
Takeaway: An insider sale of 15,000 shares generated roughly $300,670 for the CEO, executed under a 10b5-1 plan, while company results showed revenue and margin strength alongside an EPS shortfall. Analyst ratings from BTIG and Piper Sandler remain positive with price targets of $32.00 and $30.00, respectively.